Leube J, Fischer G
Pharma Division, F. Hoffmann-La Roche, Basel, Switzerland.
J Chromatogr B Biomed Appl. 1995 Mar 24;665(2):373-81. doi: 10.1016/0378-4347(94)00542-d.
The renin inhibitor Ro 42-5892 has been found to be very potent, thereby necessitating a sensitive assay method for the evaluation of its pharmacokinetics in man. We report here the development of a very sensitive and selective HPLC assay for the analysis of this compound in human plasma. Ro 42-5892 was extracted from plasma with dichloromethane, derivatized with 2,4-dinitrofluorobenzene and then chromatographed on a Novapak C18 column (150 x 3.9 mm I.D.) with acetic acid buffer (pH 7)-acetonitrile (100:85). Detection was performed by irradiation at 254 nm, followed by electrochemical oxidation at 550 mV. The extraction recovery of Ro 42-5892 from human plasma (mean 102%) was quantitative. With this method a limit of quantitation of 0.3 ng/ml was achieved. The assay was linear up to 5 ng/ml, had acceptable inter-assay precision (12.2%) and accuracy (9.3%) and was successfully tested for selectivity. This assay was successfully applied to over 250 samples from a pharmacokinetic study in hypertensive patients.
肾素抑制剂Ro 42 - 5892已被发现具有很强的效力,因此需要一种灵敏的测定方法来评估其在人体中的药代动力学。我们在此报告一种用于分析人血浆中该化合物的极其灵敏且具选择性的高效液相色谱(HPLC)测定法的开发情况。Ro 42 - 5892用二氯甲烷从血浆中萃取,用2,4 - 二硝基氟苯衍生化,然后在一根诺瓦帕克C18柱(内径150×3.9 mm)上,以乙酸缓冲液(pH 7) - 乙腈(100:85)进行色谱分析。检测通过在254 nm处照射,随后在550 mV下进行电化学氧化来完成。Ro 42 - 5892从人血浆中的萃取回收率(平均102%)是定量的。用该方法实现了0.3 ng/ml的定量限。该测定法在高达5 ng/ml时呈线性,具有可接受的批间精密度(12.2%)和准确度(9.3%),并且成功进行了选择性测试。该测定法已成功应用于来自高血压患者药代动力学研究的250多个样本。